Literature DB >> 18316591

A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.

Yinfei Tan1, Roman A Timakhov, Mamta Rao, Deborah A Altomare, Jinfei Xu, Zemin Liu, Qingshen Gao, Suresh C Jhanwar, Antonio Di Cristofano, David L Wiest, Janice E Knepper, Joseph R Testa.   

Abstract

The oncogene v-akt was isolated from a retrovirus that induced murine thymic lymphomas. Transgenic mice expressing a constitutively activated form of the cellular homologue Akt2 specifically in immature T cells develop spontaneous thymic lymphomas. We hypothesized that tumors from these mice might exhibit oncogenic chromosomal rearrangements that cooperate with activated Akt2 in lymphomagenesis. Cytogenetic analysis revealed a recurrent clonal inversion of chromosome 6, inv(6), in thymic lymphomas from multiple transgenic founder lines, including one line in which 15 of 15 primary tumors exhibited this same rearrangement. Combined fluorescence in situ hybridization, PCR, and DNA sequence analyses showed that the distal inv(6) breakpoint resides at the T-cell receptor beta chain locus, Tcrb. The proximal breakpoint maps to a region near a locus comprising the linked homeobox/transcription factor genes Dlx5 and Dlx6. Expression analysis of genes translocated to the vicinity of the Tcrb enhancer revealed that Dlx5 and Dlx6 are overexpressed in tumors exhibiting the inv(6). Experimental overexpression of Dlx5 in mammalian cells resulted in enhanced cell proliferation and increased colony formation, and clonogenic assays revealed cooperativity when both Dlx5 and activated Akt2 were coexpressed. In addition, DLX5, but not DLX6, was found to be abundantly expressed in three of seven human T-cell lymphomas tested. These findings suggest that the Dlx5 can act as an oncogene by cooperating with Akt2 to promote lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316591     DOI: 10.1158/0008-5472.CAN-07-3218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Aberrant AKT activation drives well-differentiated liposarcoma.

Authors:  Alejandro Gutierrez; Eric L Snyder; Adrian Marino-Enriquez; Yi-Xiang Zhang; Stefano Sioletic; Elena Kozakewich; Ruta Grebliunaite; Wen-Bin Ou; Ewa Sicinska; Chandrajit P Raut; George D Demetri; Antonio R Perez-Atayde; Andrew J Wagner; Jonathan A Fletcher; Christopher D M Fletcher; A Thomas Look
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.

Authors:  Yinfei Tan; Mitchell Cheung; Jianming Pei; Craig W Menges; Andrew K Godwin; Joseph R Testa
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  Identification of chromosomal translocation hotspots via scan statistics.

Authors:  Israel T Silva; Rafael A Rosales; Adriano J Holanda; Michel C Nussenzweig; Mila Jankovic
Journal:  Bioinformatics       Date:  2014-05-23       Impact factor: 6.937

4.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.

Authors:  Andrew C Hsieh; Maria Costa; Ornella Zollo; Cole Davis; Morris E Feldman; Joseph R Testa; Oded Meyuhas; Kevan M Shokat; Davide Ruggero
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

5.  Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Authors:  Douglas R Kennedy; Brian J Hartnett; Jeffrey S Kennedy; William Vernau; Peter F Moore; Thomas O'Malley; Linda C Burkly; Paula S Henthorn; Peter J Felsburg
Journal:  Vet Immunol Immunopathol       Date:  2011-04-14       Impact factor: 2.046

6.  Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.

Authors:  Shuyun Rao; Kathy Q Cai; Jason E Stadanlick; Noa Greenberg-Kushnir; Nehal Solanki-Patel; Sang-Yun Lee; Shawn P Fahl; Joseph R Testa; David L Wiest
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

Review 7.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

8.  GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Authors:  Deborah A Altomare; Lili Zhang; Jing Deng; Antonio Di Cristofano; Andres J Klein-Szanto; Rakesh Kumar; Joseph R Testa
Journal:  Clin Cancer Res       Date:  2010-01-15       Impact factor: 12.531

9.  DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Authors:  Jinfei Xu; Joseph R Testa
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

10.  Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.

Authors:  Roman A Timakhov; Yinfei Tan; Mamta Rao; Zemin Liu; Deborah A Altomare; Jianming Pei; David L Wiest; Olga O Favorova; Janice E Knepper; Joseph R Testa
Journal:  Genes Chromosomes Cancer       Date:  2009-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.